Page 151 - Read Online

Page 14 of 17 Chen et al. Hepatoma Res 2019;5:12 I http://dx.doi.org/10.20517/2394-5079.2019.03

33. Friedman GD, Hiatt RA, Quesenberry CP Jr, Selby JV, Weiss NS. Problems in assessing screening experience in observational studies
of screening efficacy: example of urinalysis screening for bladder cancer. J Med Screen 1995;2:219-23.
34. Lai MS, Yen MF, Kuo HS, Koong SL, Chen TH, et al. Efficacy of breast-cancer screening for female relatives of breast-cancer-index
cases: Taiwan multicentre cancer screening (TAMCAS). Int J Cancer 1998;78:21-6.
35. Hsu CY, Yen MF, Auvinen A, Chiu YH, Chen HH. Bayesian negative-binomial-family-based multistate Markov model for the
evaluation of periodic population-based cancer screening considering incomplete information and measurement errors. Stat Methods
Med Res 2018;27:2519-39.
36. Duffy SW, Nagtegaal ID, Wallis M, Cafferty FH, Houssami N, et al. Correcting for lead time and length bias in estimating the effect
of screen detection on cancer survival. Am J Epidemiol 2008;168:98-104.
37. Zhao C, Nguyen MH. Hepatocellular carcinoma screening and surveillance: practice guidelines and real-life practice. J Clin
Gastroenterol 2016;50:120-33.
38. Day NE, Walter SD. Simplified models of screening for chronic disease: estimation procedures from mass screening programmes.
Biometrics 1984;40:1-14.
39. Cucchetti A, Trevisani F, Pecorelli A, Erroi V, Farinati F, et al. Estimation of lead-time bias and its impact on the outcome of
surveillance for the early diagnosis of hepatocellular carcinoma. J Hepatol 2014;61:333-41.
40. Costentin CE, Layese R, Bourcier V, Cagnot C, Marcellin P, et al. Compliance with hepatocellular carcinoma surveillance guidelines
associated with increased lead-time adjusted survival of patients with compensated viral cirrhosis: a multi-center cohort study.
Gastroenterology 2018;155:431-42.e10.
41. Chen JG, Zhang SW. Liver cancer epidemic in China: past, present and future. Semin Cancer Biol 2011;21:59-69.
42. Chen JG. The selection of high risk population for liver cancer: feasibility of mass screening using alpha-fetoprotein. Chin J Prev Med
1990;24:56-7. (in Chinese)
43. Ronot M, Pommier R, Dioguardi Burgio M, Purcell Y, Nahon P, et al. Hepatocellular carcinoma surveillance with ultrasound:
costeffectiveness, high-risk populations, uptake. Br J Radiol 2018;91:20170436.
44. Tang A, Hallouch O, Chernyak V, Kamaya A, Sirlin CB. Epidemiology of hepatocellular carcinoma: target population for surveillance
and diagnosis. Abdom Radiol (NY) 2018;43:13-25.
45. Stuver S, Trichopoulos D. In: Adami HO, Hunter D, Trichopoulos D, editors. Textbook of cancer epidemiology. New York: Oxford
University Press; 2008. pp. 308-32.
46. Parkin DM, Srivatanakul P, Khlat M, Chenvidhya D, Chotiwan P, et al. Liver cancer in Thailand. I. A case-control study of
cholangiocarcinoma. Int J Cancer 1991;48:323-8.
47. Vatanasapt V, Martin N, Sriplung H, Chindavijak K, Sontipong S, et al. Cancer in Thailand 1988-1991. IARC Tech Rep No. 16, Lyon:
IARC; 1993. pp. 64-5.
48. Dondog B, Lise M, Dondov O, Baldandorj B, Franceschi S. Hepatitis B and C virus infections in hepatocellular carcinoma and
cirrhosis in Mongolia. Eur J Cancer Prev 2011;20:33-9.
49. Chuang SC, Lee YC, Hashibe M, Dai M, Zheng T, et al. Interaction between cigarette smoking and hepatitis B and C virus infection
on the risk of liver cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2010;19:1261-8.
50. Mak LY, Cruz-Ramón V, Chinchilla-López P, Torres HA, LoConte NK, et al. Global epidemiology, prevention, and management of
hepatocellular carcinoma. Am Soc Clin Oncol Educ Book 2018;38:262-79.
51. Szymañska K, Chen JG, Cui Y, Gong YY, Turner PC, et al. TP53 R249S mutations, exposure to aflatoxin, and occurrence of
hepatocellular carcinoma in a cohort of chronic hepatitis B virus carriers from Qidong, China. Cancer Epidemiol Biomarkers Prev
2009;18:1638-43.
52. Li Z, Xue J, Chen P, Chen L, Yan S, et al. Prevalence of nonalcoholic fatty liver disease in mainland of China: a meta-analysis of
published studies. J Gastroenterol Hepatol 2014;29:42-51.
53. Younes R, Bugianesi E. Should we undertake surveillance for HCC in patients with NAFLD? J Hepatol 2018;68:326-34.
54. Bird TG, Dimitropoulou P, Turner RM, Jenks SJ, Cusack P, et al. Alpha-fetoprotein detection of hepatocellular carcinoma leads to a
standardized analysis of dynamic AFP to improve screening based detection. PLoS One 2016;11:e0156801.
55. Song P, Tang Q, Feng X, Tang W. Biomarkers: evaluation of clinical utility in surveillance and early diagnosis for hepatocellular
carcinoma. Scand J Clin Lab Invest Suppl 2016;245:S70-6.
56. Zacharakis G, Aleid A, Aldossari KK. New and old biomarkers of hepatocellular carcinoma. Hepatoma Res 2018;4:65.
57. PDQ® Screening and Prevention Editorial Board. PDQ Liver (Hepatocellular) Cancer Screening (PDQ®). Bethesda, MD: National
Cancer Institute; 2018. Available from: https://www.cancer.gov/types/liver/hp/liver-screening-pdq. [Last accessed on 6 Jan 2019]
58. Heyward WL, Lanier AP, Bender TR, McMahon BJ, Kilkenny S, et al. Early detection of primary hepatocellular carcinoma by
screening for alpha-fetoprotein in high-risk families. A case-report. Lancet 1983;2:1161-2.
59. Daniele B, Bencivenga A, Magna AS, Tinessa V. Αlpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma.
Gastroenterology 2004; 127:S108-12.
60. Kondo Y, Kimura O, Shimosegawa T. Significant biomarkers for the management of hepatocellular carcinoma. Clin J Gastroenterol
2015;8:109-15.
61. Fu J, Wang H. Precision diagnosis and treatment of liver cancer in China. Cancer Lett 2018;412:283-8.
62. Schütte K, Schulz C, Link A, Malfertheiner P. Current biomarkers for hepatocellular carcinoma: surveillance, diagnosis and prediction
of prognosis. World J Hepatol 2015;7:139-49.
63. Gupta S, Bent S, Kohlwes J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis
C. A systematic review and critical analysis. Ann Intern Med 2003;139:46-50.
64. Huang YC, Huang CF, Chang KC, Hung SF, Wang JH, et al. Community-based screening for hepatocellular carcinoma in elderly
residents in a hepatitis B-and C-endemic area. J Gastroenterol Hepatol 2011;26:129-34.